Effect of Memantine versus Placebo on the Outcome and Functional Recovery of Patients with Intracranial hemorrhage: a double-blind randomized placebo-controlled pilot trial

Deputy of research, Guilan University of Medical Sciences0 个研究点目标入组 60 人开始时间: 待定最近更新: 2018年2月22日

适应症

试验速览

暂无简介。

•The inclusion criteria:
•1. Patients with the diagnosis of first ever, spontaneous, non-traumatic supratentorial ICH confirmed by a clinical examination and radiological findings
•2. Admission NIHSS <20
•3. Patients whom diagnosis is made within less than 6 hours after onset of symptoms
•4. Patients with a length of hospital stay of at least 7 days
•5. Age <80
•6. Admission GCS >5
•7. Admission hematoma volume <30 cc
•Patients who will not include:
•1.Those with previous or concomitant ischemic stroke
•2.Those with other systemic disease including liver or kidney failure
•3. Those who have pace maker, or suffer from severe neuropathy, systemic vascular disease or major affective disorders.
•4. Those with a positive history of severe disability due to neurological or non-neurological causes
•5.Those with a previous history of ICH, myocardial infarction or ischemic stroke
•6. Those who abuse alcohol
•7. Those with confirmed diagnosis of cognitive disorders based on DSM-IV criteria for dementia or IQCODE questionnaire
•8. Those with ICH secondary to brain trauma or rupture of brain aneurysm
•9. Those with a history of using anticoagulant drugs, antiplatelet drugs and NSAIDs.
•10. Pregnant patients
•11. Those with concomitant Intraventricular hemorrhage (IVH)
•12.Deep coma
•Exclusion criteria:
•1. Refusal to continue with the study
•2. The occurrence of serious adverse drug affects at any time during the study.
•3. Alcohol abuse during the study period

发起方

Deputy of research, Guilan University of Medical Sciences